Skyline Advisors
  • Services
  • Team
  • Transactions
  • Industries
  • Reports
  • News
    • Capital Markets
    • Firm News
    • Resources
  • Contact
    • Newsletter
  • us

Partners for Strategic Transactions

Four More Biotech Firms Added to the Industry’s 2018 IPO Total

7/23/2018

 
​Crinetics Pharmaceuticals, Rubius Therapeutics, Constellation Pharmaceuticals, and Allakos all debuted shares on the NASDAQ last week. Three of the four firms are clinical-stage, with the exception being Rubuis. Crinetics, Rubius, and Allakos all raised over $100 million in their initial public offerings
  • Clinical-stage biotech firm Crinetics Pharmaceuticals began trading shares on the NASDAQ last Wednesday under the symbol “CRNX.” Founded in 2008, Crinetics is focused on the discovery, development and commercialization of novel therapeutics or rare endocrine diseases and endocrine-related tumors. Their drugs work by targeting peptide hormone receptors, also known as endocrine G-protein coupled receptors (GPCRs). The San Diego company issued six million shares, raising $102 million.

  • On Wednesday, Rubius Therapeutics, a biotechnology company developing red blood cell therapies, debuted on the NASDAQ under the symbol “RUBY.” The firm sold 10.5 million shares, raising $241 million, exceeding its $200 million goal. What is unique about the IPO is that Rubius is still in a preclinical stage, an uncommon trait for most biotech firms going public. Rubius’ lead programs are using engineered red blood cell therapeutics to target rare enzymatic diseases caused by a single genetic defect that result in the inactivation of a critical metabolic enzyme or bioactive protein.

  • Constellation Pharmaceuticals, a Boston-area clinical stage biotech company, raised $60 million in their IPO on a 4-million-share offering. The VC-backed firm uses expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Constellation originally intended to raise $80 million off the sale of 5.34 million shares; however, the company elected to downsize the offering to four million shares at $15 per share.
​
  • In an upsized IPO, Allakos raised $127.8 million, valuing the firm at $750 million based on its initial public price. Operating out of the Bay Area, Allakos is a developer of antibody therapeutics for allergic and inflammatory diseases. The company’s initial clinical focus is eosinophilic gastritis, an inflammatory disease of the gastrointestinal tract, as well as other trials with other mast cell and eosinophil-driven diseases. The company plans to use the funds raised for mid-stage trials of its flagship eosinophilic gastritis drug. 

Comments are closed.

    Archives

    May 2023
    May 2022
    January 2022
    November 2021
    August 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    December 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017

    Categories

    All
    Auto Sales
    Bankruptcies
    Capital Markets
    Confidence
    Corporate Profits
    Debt
    Economy
    GDP
    Holiday
    Housing
    Industrial Production
    Inflation
    Initial Public Offerings
    Interest Rates
    Inventories
    Jobs
    Manufacturing
    Mergers And Acquisitions
    Middle Market
    Prices
    Private Equity
    Productivity
    Retail Spending
    Rural Economy
    Small Business
    Stock Market
    Taxes
    Trade
    Venture Capital
    Wages

    RSS Feed

Picture
​Skyline Advisors is a division of Ideation Ventures, Inc. Services involving securities are offered through M&A Securities Group, Inc.4151 N Mulberry Drive Suite 252, Kansas City, MO, 64116  (“MAS") . Services involving real estate brokerage are offered through Berkshire Hathaway HomeServices Ambassador Real Estate ("BHHS"). Skyline, MAS, and BHHS are separate entities. 
​

COPYRIGHT 2024. ALL RIGHTS RESERVED.
Virtual Data Room
Company   Services   Team   Transactions   Industries   Reports   News
Photo from inkknife_2000 (8.5 million views +)
  • Services
  • Team
  • Transactions
  • Industries
  • Reports
  • News
    • Capital Markets
    • Firm News
    • Resources
  • Contact
    • Newsletter
  • us